KROS
Keros Therapeutics, Inc. · Healthcare · Market cap $221.7M
Insiders sold $160K net in the last 90 days ·7 sellers, 1 buyer· 5 of 8 sales under Rule 10b5-1 plans· latest Form 4 filed Aug 20, 2026
Insider Buying
$76K
reported purchases (SEC code P)
Insider Selling
$523K
reported sales (SEC code S)
Unique Insiders
10
in the rolling window
Latest filing
Aug 20, 2026
Cho Esther
Keros Therapeutics, Inc. (KROS) has 29 SEC Form 4 filings (32 transaction rows) in the rolling window, disclosed by 10 distinct insiders. Most recent filing: Aug 20, 2026.
Inside the rolling window, 10 insiders at Keros Therapeutics, Inc. reported 6 open-market purchases totaling $76K and 12 open-market sales totaling $523K. The most active filer is Director BIENAIME JEAN JACQUES with 6 filings. Insiders have net sold $115K over the trailing 6 months. The most recent open-market filing is a sale of 4,485 shares by Chief Legal Officer Cho Esther, dated Aug 18, 2026, worth $46K.
- Industry:Biotechnology
- CEO:Jasbir S. Seehra
- Employees:92
- HQ:Lexington, MA, US
- IPO:2020-04-08
| Source | |||||||
|---|---|---|---|---|---|---|---|
Cho EstherFirst in 6 months | Chief Legal Officer | Sale | 4,485 | $46K | Aug 20 | +2.1% | SEC ↗ |
Lerner Lorena RaquelFirst in 6 months | Chief Scientific Officer | Sale | 3,568 | $37K | Aug 20 | +2.1% | SEC ↗ |
Tanini AnnitaFirst filing | Corp. Controller & VP, Finance | Sale | 1,224 | $13K | Aug 20 | +2.1% | SEC ↗ |
| Director | Sale | 551 | $6K | Aug 20 | +2.1% | SEC ↗ | |
| Director | Purchase | 1,000 | $10K | Aug 19 | +0.7% | SEC ↗ | |
| Director | Purchase | 1,000 | $11K | Jul 17 | +5.1% | SEC ↗ | |
| Director | Purchase | 1,000 | $10K | Jun 17 | +7.4% | SEC ↗ | |
Newton Charles W.First filing | Director | Sale | 550 | $6K | Jun 15 | +9.2% | SEC ↗ |
Knowles JuliusFirst filing | Director | Sale | 2,625 | $28K | Jun 8 | +11.8% | SEC ↗ |
Farzan NimaFirst filing | Director | Sale | 2,625 | $28K | Jun 8 | +11.8% | SEC ↗ |
Seth AlpnaFirst filing | Director | Sale | 2,625 | $28K | Jun 5 | — | SEC ↗ |
| Director | Purchase | 1,000 | $11K | May 19 | — | SEC ↗ | |
| Director | Purchase | 1,000 | $12K | Apr 17 | — | SEC ↗ | |
BIENAIME JEAN JACQUESFirst filing | Director | Purchase | 2,000 | $22K | Mar 11 | — | SEC ↗ |
Lerner Lorena RaquelFirst filing | Chief Science Officer | Sale | 3,873 | $63K | Feb 20 | — | SEC ↗ |
Regnante KeithFirst filing | CHIEF FINANCIAL OFFICER | Sale | 4,739 | $77K | Feb 20 | — | SEC ↗ |
Cho EstherFirst filing | SVP, General Counsel | Sale | 4,745 | $78K | Feb 20 | — | SEC ↗ |
Seehra JasbirFirst filing | CHIEF EXECUTIVE OFFICER | Sale | 7,015 | $113K | Feb 20 | — | SEC ↗ |
Earnings: last 7 quarters
Frequently asked questions
How many SEC Form 4 insider filings does KROS have?
Keros Therapeutics, Inc. (KROS) has 29 SEC Form 4 filings (32 transaction rows) in the rolling 365-day window, disclosed by 10 distinct insiders. Most recent filing: Aug 20, 2026.
When was the most recent SEC Form 4 filing for KROS?
The most recent Form 4 filing for KROS on Tracefour is dated Aug 20, 2026.
Who is the most active insider at KROS?
The most active SEC Form 4 filer at KROS in the rolling window is Director BIENAIME JEAN JACQUES, with 6 filings.
What is the net insider flow at KROS over the last 6 months?
Over the trailing 180 days, insiders at KROS have net sold $115K based on SEC Form 4 disclosures.
What is the total insider buy and sell value at KROS in the current window?
Inside the rolling window, insiders at KROS bought $76K and sold $523K based on SEC Form 4 filings.
Can I get alerts for KROS insider trading?
Yes. Tracefour sends a free email when a new SEC Form 4 purchase or sale is filed at Keros Therapeutics, Inc. (KROS). Alerts are set per company from the page itself, there is no paid tier, and each email links to the original filing on SEC EDGAR.
Related companies
Keros Therapeutics, Inc. is in the Healthcare sector.